Drugs / Vaccine Enhancement Patch
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01353534 | May → Dec 2011 | — | Intercell USA, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaccine Enhancement Patch | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01353534 ↗ |
| Known as | VEP | “The VEP (Vaccine Enhancement Patch) contains 50 mcg LT (heat-labile enterotoxin of E. coli)” NCT01353534 ↗ |
| Route | Topical | “topical application of a VEP at the vaccination site” NCT01353534 ↗ |